Wu Bingchen, Wang Zizong, Xu Hanlin, Chu Xiangyang, Jiang Qiwen
Department of Oncology, Hospital of Chinese Medicine of Changxing County, Huzhou, Zhejiang, China.
Department of Thoracic Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Histol Histopathol. 2023 Dec;38(12):1453-1464. doi: 10.14670/HH-18-604. Epub 2023 Mar 3.
Lung cancer, one of the most frequently diagnosed cancers, causes a huge number of mortalities globally. Among lung cancers, non-small cell lung cancer (NSCLC) is the most recorded. Despite accumulating research, the molecular basis of NSCLC progression remains poorly known. Therefore, we aim to assess the function of NCK1-AS1 in NSCLC and elucidate the molecular mechanism. Firstly, we quantified the NCK1-AS1 level in tumors and adjacent healthy tissues. NCK1-AS1 was significantly upregulated in NSCLC tumors, which was associated with poor prognosis in patients. Silencing NCK1-AS1 significantly inhibited the proliferation, migration, and invasion, as well as the EMT of NSCLC cell lines. Starbase bioinformatic prediction revealed that NCK1-AS1 targets miR-361-5p which acts to regulate ADAM10 gene expression. Our result showed that NCK1-AS1 upregulation markedly reduced miR-361-5p mRNA expression, while increasing ADAM10 expression. For the first time, we demonstrated that NCK1-AS1 regulates the miR-361-5p/ADAM10 axis, thereby promoting NSCLC progression. NCK1-AS1 might be developed as a therapeutic target for treating NSCLC.
肺癌是最常被诊断出的癌症之一,在全球范围内导致大量死亡。在肺癌中,非小细胞肺癌(NSCLC)的记录最为常见。尽管研究不断积累,但NSCLC进展的分子基础仍知之甚少。因此,我们旨在评估NCK1-AS1在NSCLC中的功能并阐明其分子机制。首先,我们对肿瘤组织和相邻健康组织中的NCK1-AS1水平进行了定量。NCK1-AS1在NSCLC肿瘤中显著上调,这与患者的不良预后相关。沉默NCK1-AS1可显著抑制NSCLC细胞系的增殖、迁移和侵袭以及上皮-间质转化(EMT)。Starbase生物信息学预测显示,NCK1-AS1靶向miR-361-5p,后者可调节ADAM10基因表达。我们的结果表明,NCK1-AS1的上调显著降低了miR-361-5p mRNA表达,同时增加了ADAM10表达。我们首次证明,NCK1-AS1通过调节miR-361-5p/ADAM10轴,从而促进NSCLC进展。NCK1-AS1可能会被开发为治疗NSCLC的治疗靶点。